Mylan NV (NASDAQ:MYL) (Trend Analysis) shares were traded with a significant increase in volume. The stock closed last trading session at $38.28, down by -1.64%, with a volume of 11,888,355 shares against an average amount for the last three months of 7,513,750.
Stock Performance: Click here for a free comprehensive Trend Analysis Report
Mylan NV (NASDAQ:MYL) stock is currently trading 31.04% below its 52-week-high, 13.93% above its 52-week-low. The 1-year stock price history is in the range of $33.6 – $55.51. Mylan NV (MYL) has a price to earnings ratio of 24.23 versus Healthcare sector average of 40.79. MYL stock price has underperformed the Nasdaq by 35.2%. The Generic Drugs company is currently valued at $20.48 billion, and its share price closed the last trading session at $38.28. The stock has a 50-day moving average of $38.02 and a 200-day moving average of $42.58.
Mylan NV (MYL) current short interest stands at 27.34 million shares. It has increased by 6% from the same period of last month. Around 8% of the company’s shares, which are float, are short sold. With a 10-days average volume of 9.47 million shares, the number of days required to cover the short positions stand at 2.9 days.
Mylan NV (MYL) declared last quarter earnings on November 09. The Generic Drugs company announced last quarter earnings per share of $1.38 against a consensus Street estimate of $1.50, missing estimate by $0.12. The company posted a revenue of $3.06 billion compared to an estimation of $3.23 billion.
Is this a Trading Opportunity? Click here for a free Trend Analysis Report
There are currently twenty-two analysts that cover Mylan NV stock. Of those twenty-two, fourteen have a Buy rating, eight have a Hold rating. On a consensus basis this yields to an Overweight rating. The consensus target price stands at $52.44.
A recent analyst activity consisted of Mizuho Securities who initiated their coverage on the stock with Buy rating on October 26. Mizuho Securities fixed their price target at $49. This corresponds to a 28% upside from the last closing price. On the date of report, the stock closed at $38.08.
Raymond James upgraded their Market Perform rating to Strong Buy on October 10. On the date of report, the stock closed at $38.87.
Another research firm was RBC Capital who reiterated their Sector Perform stance on October 10. RBC Capital fixed their price target at $48. This translates to a 25.39% upside from the last closing price. On the date of report, the stock closed at $38.87.
Mylan NV is a global generic and specialty pharmaceuticals company. The Company operates an active pharmaceutical ingredient manufacturer and runs a specialty business focused on respiratory, allergy, and psychiatric therapies.